The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets.
Clinical observation shows that radiographic contrast media (CM) may influence thrombus formation. In the search for the underlying mechanism, we have shown that the ionic CM ioxaglate is a potent inhibitor of thrombin generation in platelet-poor and platelet-rich plasma, whereas the influence of the non-ionic contrast medium iodixanol is minimal. Ioxaglate boosts the inhibitory effect of the platelet GPIIb/IIIa antagonist abciximab and the effects of ioxaglate and heparin are additive. Ioxaglate inhibits the clotting of fibrinogen and the activation of factors V and VIII, and of platelets by thrombin. It does not inhibit hydrolysis of small chromogenic thrombin substrates, nor does it influence the heparin-catalyzed inactivation of thrombin by antithrombin. We assume therefore that ioxaglate interferes with the binding of macromolecular substrates to the anionic exosite I of thrombin. The biological correlation to the observed antithrombotic effect of ioxaglate is then to be found in the inhibition of thrombin generation via inhibition of thrombin-mediated feedback activations.
Al Dieri
R
R
Cardiovascular Research Institute (CARIM), Synapse BV, Maastricht University, Maastricht, The Netherlands.
Béguin
S
S
Hemker
H C
HC
D000077284:Abciximab; D000792:Angiography / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D005165:Factor V / Q000378:metabolism*; D005169:Factor VIII / Q000378:metabolism*; D005246:Feedback; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology; D006493:Heparin / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000494:pharmacology; D066298:In Vitro Techniques; D007485:Ioxaglic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology; D013917:Thrombin / Q000378:metabolism*; D013927:Thrombosis / Q000097:blood / Q000209:etiology
D000911:Antibodies, Monoclonal; D003287:Contrast Media; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D005165:Factor V; D005169:Factor VIII; D006493:Heparin; D013917:Thrombin; D000077284:Abciximab; D007485:Ioxaglic Acid